David OMalley, Director for Translational & Clinical Research Partnerships, Leader, Clinical Trial Innovation at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“New review in Cancer Research (DOI: 10.1158/0008-5472.CAN-25-4426), amazing co-authors (Melanie Flint, Domenica Lorusso, Susan Lutgendorf, Alexander Olawaiye, Adrian Jubb, and Premal Thaker).
Tumors hijack glucocorticoid receptor signaling to resist chemotherapy and suppress antitumor immunity. Selective GR antagonists like relacorilant reverse both: blocking the antiapoptotic SGK1/DUSP1 pathway to restore chemo sensitivity, and reactivating exhausted T cells to counter immune evasion.
Translating to improved PFS/OS in ROSELLA.”
Other articles featuring David OMalley on OncoDaily.